Holding(s) in Company

RNS Number : 4029H
Hikma Pharmaceuticals Plc
13 March 2015
 



 

Notification of major interests in shares

 

LONDON, 13 March 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

 

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

 

 

 

2

Reason for the notification



An acquisition or disposal of voting rights

Yes


An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached

No


An event changing the breakdown of voting rights

No


Other (please specify): Compliance with the Transparency Directive

No

 

 

3

Full name of the person subject to the notification obligation

FMR LLC

4

Full name of shareholders

See attached schedule

5

Date of the Transaction (and date on which the threshold crossed is reached differently)

11 March 2015

6

Date on which the issuer notified

13 March 2015

7

Threshold that is crossed

5%

8

Notified details

See A, B & C below




A. Voting rights attached to shares

Class type of shares (if possible using the ISIN code)

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of shares

Number of voting rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

Direct

Indirect

Ordinary Shares (0.10 GBP)

GB00B0LCW083

9,750,718

9,750,718

-

9,958,877

-

9,958,877

-

5.01

 

B. Qualifying Financial instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights that may be acquired if the instrument if exercised/converted

% of voting rights

-

-

-

-

-

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise Price

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights instrument refers to

% of voting rights

Nominal           

Delta

-

-

-

-

-

-

-

 

Total A+B+C

Number of Voting rights

% of voting rights

9,958,877

5.01%

 

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable



 

Proxy Voting

10

Name of the proxy holder

 

Custodian

Day to Day IM

Total

BANK OF NEW YORK BRUSSELS (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

8,051

BANK OF NEW YORK MELLON

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

156,712

BROWN BROTHERS HARRIMAN AND CO

FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC.

23,517


FMRC-FMR CO., INC

39,085


PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

68,320


PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

853,028

CIBC MELLON TRUST (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

19,726

CITIBANK NA, HONG KONG BR (S)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

21,821

JP MORGAN, BOURNEMOUTH (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

13,981


PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

207,940

JPMORGAN CHASE BANK

FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC.

151,087


FMRC-FMR CO., INC

3,377,248


PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

42,456


PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

83,696

MELLON BANK NA (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

388,798

NATIONAL BANK TRUST (C)

PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

20,969

NOMURA TRUST AND BANKING (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

261

NORTHERN TRUST CO (C)

FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC.

2,694,515


FMRC-FMR CO., INC

150,915


PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

31,017


PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

340,807

STATE STREET BANK AND TR CO

FMRC-FMR CO., INC

243,910


PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

456,774


PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

540,997

US BANK NA (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

23,246

Grand Total


9,958,877

 

 

11

Number of voting rights proxy holder will cease to hold

N/A

12

Date on which proxy holder will cease to hold voting rights

N/A

 

13

Additional Information


14

Contact name:

Peter Speirs, Company Secretary

15

Contact telephone number:

020 7399 2772

 

- ENDS -



About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.  

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOOARVAAOAAR
UK 100

Latest directors dealings